Clinical Trials
8 trialsNCT06788912 2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06305754 2026-05-29
MK-2870-009
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06824467 2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05319730 2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT03258593 2026-03-17
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04743661 2026-02-05
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Pediatric Brain Tumor Consortium
Phase 2 Active not recruiting
NCT04568902 2025-10-23
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Eisai Inc.
Phase 1 Completed
NCT01059786 2025-06-12
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting